Crizanlizumab

Pfizer's sudden withdrawal of Oxbryta, a sickle cell disease drug, raises concerns over patient trust and treatment safety. The abrupt removal, following European regulatory flags, poses risks like severe anemia if patients stop abruptly. Pfizer's lack of transparency and the FDA's limited notice add to the uncertainty, potentially impacting future sickle cell treatments and clinical trials.

Pfizer withdraws sickle cell drug Oxbryta from global market due to safety concerns, leaving patients and advocates scrambling. The decision follows EMA review highlighting increased vaso-occlusive crisis cases. Pfizer pauses ongoing clinical trials and shuts down expanded access programs. The FDA advises against prescribing Oxbryta and recommends alternative treatments.

Pfizer is withdrawing Oxbryta, a sickle cell disease drug, due to safety concerns, leading to an imbalance of deaths and vaso-occlusive crises. The European Medicines Agency recommended suspending its clearance. Pfizer acquired Oxbryta through its purchase of Global Blood Therapeutics in 2022, with Oxbryta generating $92 million in revenue in Q2 2024. Pfizer continues to develop other sickle cell treatments, including inclacumab and osivelotor in Phase 3. Patients currently on Oxbryta should consult their doctors for alternatives.